T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$4.01B |
| 2 |
Broadcom
AVGO
|
+$1.49B |
| 3 |
GE Vernova
GEV
|
+$1.19B |
| 4 |
International Paper
IP
|
+$1.05B |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$952M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.31B |
| 2 |
Constellation Energy
CEG
|
+$1.94B |
| 3 |
Qualcomm
QCOM
|
+$1.74B |
| 4 |
NVIDIA
NVDA
|
+$1.71B |
| 5 |
Salesforce
CRM
|
+$1.5B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.98% |
| 2 | Healthcare | 14.89% |
| 3 | Financials | 10.35% |
| 4 | Consumer Discretionary | 10.11% |
| 5 | Communication Services | 9.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2126
Viridian Therapeutics
VRDN
$2.49B
| $578K | ﹤0.01% |
44,419
+13,050
| +42% | +$181K |
|
2127
Adaptive Biotechnologies
ADPT
$4.02B
| $575K | ﹤0.01% |
158,807
+3,578
| +2% | +$11.4K |
|
2128
Acco Brands
ACCO
$399M
| $574K | ﹤0.01% |
121,937
+3,151
| +3% | +$15.7K |
|
|
SVC
2129
Service Properties Trust
SVC
$1.06B
| $572K | ﹤0.01% |
22,230
+2,116
| +11% | +$60.8K |
|
|
UMH
2130
UMH Properties
UMH
$1.39B
| $571K | ﹤0.01% |
35,689
+3,112
| +10% | +$48.4K |
|
|
JAMF
2131
DELISTED
Jamf
JAMF
| $570K | ﹤0.01% |
34,488
+3,382
| +11% | +$59.2K |
|
2132
Janus International
JBI
$664M
| $570K | ﹤0.01% |
45,095
+20,817
| +86% | +$291K |
|
2133
Kforce
KFRC
$1.03B
| $570K | ﹤0.01% |
9,166
+596
| +7% | +$37.8K |
|
|
PRA
2134
DELISTED
ProAssurance
PRA
| $570K | ﹤0.01% |
46,636
+2,313
| +5% | +$31.4K |
|
2135
Trump Media & Technology Group
DJT
$2.31B
| $570K | ﹤0.01% |
+17,383
| New | +$730K |
|
2136
Xperi
XPER
$321M
| $568K | ﹤0.01% |
69,166
+6,318
| +10% | +$59.7K |
|
2137
Ecovyst
ECVT
$1.09B
| $567K | ﹤0.01% |
63,122
+10,524
| +20% | +$102K |
|
2138
Century Aluminum
CENX
$4.59B
| $566K | ﹤0.01% |
33,763
-250
| -0.7% | -$4.26K |
|
2139
Central Pacific Financial
CPF
$1B
| $558K | ﹤0.01% |
26,320
+813
| +3% | +$16.4K |
|
2140
Forrester Research
FORR
$220M
| $557K | ﹤0.01% |
32,607
+3,348
| +11% | +$61.5K |
|
2141
PRA Group
PRAA
$762M
| $557K | ﹤0.01% |
28,327
+1,168
| +4% | +$26.9K |
|
2142
Unitil
UTL
$984M
| $557K | ﹤0.01% |
10,749
+460
| +4% | +$23.6K |
|
2143
Arcus Biosciences
RCUS
$3.67B
| $556K | ﹤0.01% |
36,498
+1,734
| +5% | +$28K |
|
2144
Digimarc Corp
DMRC
$167M
| $555K | ﹤0.01% |
17,871
+2,686
| +18% | +$68.3K |
|
2145
Heritage Financial
HFWA
$1.22B
| $554K | ﹤0.01% |
30,706
+922
| +3% | +$16.5K |
|
2146
Crescent Energy
CRGY
$3.98B
| $550K | ﹤0.01% |
46,363
+8,364
| +22% | +$98.4K |
|
2147
Pathward Financial
CASH
$1.78B
| $549K | ﹤0.01% |
9,689
+509
| +6% | +$26.8K |
|
2148
Arcutis Biotherapeutics
ARQT
$3.3B
| $548K | ﹤0.01% |
58,902
+11,149
| +23% | +$101K |
|
|
HSII
2149
DELISTED
Heidrick & Struggles
HSII
| $548K | ﹤0.01% |
17,350
+674
| +4% | +$22K |
|
2150
Amneal Pharmaceuticals
AMRX
$6.15B
| $547K | ﹤0.01% |
86,027
+4,763
| +6% | +$30.2K |
|
Similar funds
T. Rowe Price Associates's Q2 2024 Portfolio in Review
As of Q2 2024, T. Rowe Price Associates held 3,089 positions worth $836B, up 2.4% from $816B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
T. Rowe Price Associates's Q2 2024 filing shows 135 new, 1,850 increased, 836 reduced and 113 closed positions. Its largest new stake was Tempus AI: 5,227,120 shares worth $183M. The largest sale was Microsoft, an estimated $2.31B.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2024 buy was Tempus AI: 5,227,120 shares worth $183M.
- T. Rowe Price Associates added most to Apple in Q2 2024, an estimated $4.01B increase.
- T. Rowe Price Associates's biggest Q2 2024 reduction was Microsoft, cutting an estimated $2.31B.
- T. Rowe Price Associates fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $570M.
- T. Rowe Price Associates's ten largest holdings make up 36% of its $836B portfolio in Q2 2024.
- T. Rowe Price Associates opened 135 new positions and closed 113 in Q2 2024.
- T. Rowe Price Associates's portfolio value rose 2.4% quarter-over-quarter to $836B.
Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.